INTERVENTION 1:	Intervention	0
Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1	Intervention	1
ixabepilone	CHEBI:63605	0-11
doxorubicin	CHEBI:28748,BAO:0000639	24-35
Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days	Intervention	2
ixabepilone	CHEBI:63605	0-11
doxorubicin hydrochloride	CHEBI:31522	52-77
day	UO:0000033	103-106
day	UO:0000033	118-121
ixabepilone: Given IV	Intervention	3
ixabepilone	CHEBI:63605	0-11
pegylated liposomal doxorubicin hydrochloride: Given IV	Intervention	4
doxorubicin hydrochloride	CHEBI:31522	20-45
INTERVENTION 2:	Intervention	5
Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2	Intervention	6
ixabepilone	CHEBI:63605	0-11
doxorubicin	CHEBI:28748,BAO:0000639	24-35
Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days	Intervention	7
ixabepilone	CHEBI:63605	0-11
doxorubicin hydrochloride	CHEBI:31522	52-77
day	UO:0000033	103-106
day	UO:0000033	118-121
ixabepilone: Given IV	Intervention	8
ixabepilone	CHEBI:63605	0-11
pegylated liposomal doxorubicin hydrochloride: Given IV	Intervention	9
doxorubicin hydrochloride	CHEBI:31522	20-45
Inclusion Criteria:	Eligibility	0
Histologically or cytologically confirmed diagnosis of 1 of the following: advanced ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer (phase I and II) or metastatic breast cancer (phase I only).	Eligibility	1
peritoneal cavity	UBERON:0001179	112-129
fallopian tube cancer	DOID:1964	134-155
breast cancer	DOID:1612	187-200
Platinum- and taxane-resistant disease, defined as a disease-free interval of < 6 months after completion of platinum- and taxane-based chemotherapy. Disease progression during the regimen (phase II) or previously treated with >= 2 prior regimens for metastatic breast cancer, including 1 taxane-based regimen in the adjuvant or metastatic setting (phase I).	Eligibility	2
disease	DOID:4,OGMS:0000031	31-38
disease	DOID:4,OGMS:0000031	53-60
disease	DOID:4,OGMS:0000031	150-157
breast cancer	DOID:1612	262-275
adjuvant	CHEBI:60809	317-325
Meets 1 of the following criteria: Previously treated with a standard course of taxane- and platinum-based chemotherapy for ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer, that is platinum-refractory or -sensitive disease (phase I );	Eligibility	3
peritoneal cavity	UBERON:0001179	152-169
fallopian tube cancer	DOID:1964	174-195
disease	DOID:4,OGMS:0000031	239-246
Measurable or evaluable disease, meeting 1 of the following criteria: unidimensionally measurable lesion, known disease and CA 125 > 50 U/mL on 2 occasions >= 1 week apart or known disease and CA 27-29, CA 15-3, or CA 125 > 50 U/mL on 2 occasions >= 1 week apart (for breast cancer patients)	Eligibility	4
disease	DOID:4,OGMS:0000031	24-31
disease	DOID:4,OGMS:0000031	112-119
disease	DOID:4,OGMS:0000031	181-188
week	UO:0000034	161-165
week	UO:0000034	252-256
breast cancer	DOID:1612	268-281
ECOG 0-2 or Karnofsky 60-100%	Eligibility	5
At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered.	Eligibility	6
mitomycin	CHEBI:25357	71-80
At least 1 week since prior chemotherapy if given on a daily or weekly schedule and recovered.	Eligibility	7
week	UO:0000034	11-15
week	UO:0000034	64-68
At least 3 weeks since prior radiotherapy and recovered.	Eligibility	8
radiotherapy	OAE:0000235	29-41
Recovered for more than 4 weeks from all adverse events related to prior agents.	Eligibility	9
Normal organ function including:	Eligibility	10
organ	UBERON:0000062	7-12
function	BAO:0003117,BFO:0000034	13-21
Normal bilirubin	Eligibility	11
WBC >= 3,000/mm3	Eligibility	12
Absolute neutrophil count >= 1,500/mm3	Eligibility	13
Platelet count >= 100,000/mm3	Eligibility	14
platelet count	CMO:0000029	0-14
AST and ALT =< 2.5 times upper limit of normal (ULN)	Eligibility	15
Creatinine =< 1.5 times ULN or Creatinine clearance  60 mL/min	Eligibility	16
creatinine	CHEBI:16737	0-10
creatinine	CHEBI:16737	31-41
creatinine clearance	CMO:0000765	31-51
Exclusion criteria:	Eligibility	17
No other concurrent investigational agents.	Eligibility	18
No concurrent combination antiretroviral therapy for HIV-positive patients.	Eligibility	19
No other concurrent anticancer therapy.	Eligibility	20
Has received a previous chemotherapy regimen for this cancer that included drugs such as docetaxel or paclitaxel.	Eligibility	21
cancer	DOID:162	54-60
paclitaxel	CHEBI:45863	102-112
Life expectancy of more than 3 months	Eligibility	22
No symptomatic congestive heart failure	Eligibility	23
congestive heart failure	HP:0001635,DOID:6000	15-39
No unstable angina pectoris	Eligibility	24
angina pectoris	HP:0001681	12-27
No cardiac arrhythmia	Eligibility	25
arrhythmia	HP:0011675	11-21
Not pregnant or nursing	Eligibility	26
Fertile patients must use effective contraception	Eligibility	27
No history of allergic reaction attributed to compounds of similar chemical or biological composition to CremophorÂ® or study drugs	Eligibility	28
history	BFO:0000182	3-10
No neuropathy >= grade 2	Eligibility	29
neuropathy	DOID:870	3-13
No ongoing or active infection	Eligibility	30
active	PATO:0002354	14-20
No psychiatric illness or social situation that would preclude study compliance.	Eligibility	31
No other uncontrolled illness.	Eligibility	32
No active brain metastases, including any of the following: evidence of cerebral edema by CT scan or MRI, evidence of disease progression on prior imaging studies, requirement for steroids or clinical symptoms of brain metastasis.	Eligibility	33
active	PATO:0002354	3-9
brain	UBERON:0000955	10-15
brain	UBERON:0000955	213-218
cerebral edema	HP:0002181	72-86
ct	BAO:0002125	4-6
ct	BAO:0002125	90-92
disease	DOID:4,OGMS:0000031	118-125
Outcome Measurement:	Results	0
Incidence of Dose-limiting Toxicity (DLT), Graded Using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 4.0 (Phase I)	Results	1
cancer	DOID:162	69-75
Dose-Limiting Toxicities are assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events classification and usually encompasses all grade 3 or higher toxicities	Results	2
cancer	DOID:162	64-70
Time frame: 28 days	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: Ixabepilone 24mg/m2 and Doxorubicin 30mg/m2: Level 1	Results	5
ixabepilone	CHEBI:63605	17-28
doxorubicin	CHEBI:28748,BAO:0000639	41-52
Arm/Group Description: Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days	Results	6
ixabepilone	CHEBI:63605	23-34
doxorubicin hydrochloride	CHEBI:31522	75-100
day	UO:0000033	126-129
day	UO:0000033	141-144
ixabepilone: Given IV	Results	7
ixabepilone	CHEBI:63605	0-11
pegylated liposomal doxorubicin hydrochloride: Given IV	Results	8
doxorubicin hydrochloride	CHEBI:31522	20-45
Overall Number of Participants Analyzed: 6	Results	9
Measure Type: Number	Results	10
Unit of Measure: participants  1	Results	11
Results 2:	Results	12
Arm/Group Title: Ixabepilone 32mg/m2 and Doxorubicin 30mg/m2: Level 2	Results	13
ixabepilone	CHEBI:63605	17-28
doxorubicin	CHEBI:28748,BAO:0000639	41-52
Arm/Group Description: Ixabepilone IV over 3 hours and pegylated liposomal doxorubicin hydrochloride IV over 30-60 minutes on day 1 every 21 days	Results	14
ixabepilone	CHEBI:63605	23-34
doxorubicin hydrochloride	CHEBI:31522	75-100
day	UO:0000033	126-129
day	UO:0000033	141-144
ixabepilone: Given IV	Results	15
ixabepilone	CHEBI:63605	0-11
pegylated liposomal doxorubicin hydrochloride: Given IV	Results	16
doxorubicin hydrochloride	CHEBI:31522	20-45
Overall Number of Participants Analyzed: 6	Results	17
Measure Type: Number	Results	18
Unit of Measure: participants  1	Results	19
Adverse Events 1:	Adverse Events	0
Total: 6/6 (100.00%)	Adverse Events	1
Anemia1/6 (16.67%)	Adverse Events	2
Constipation1/6 (16.67%)	Adverse Events	3
Mucositis1/6 (16.67%)	Adverse Events	4
Vomiting0/6 (0.00%)	Adverse Events	5
Dehydration0/6 (0.00%)	Adverse Events	6
Abdominal pain0/6 (0.00%)	Adverse Events	7
Small intestinal obstruction0/6 (0.00%)	Adverse Events	8
Nausea0/6 (0.00%)	Adverse Events	9
Ascites0/6 (0.00%)	Adverse Events	10
Diarrhea0/6 (0.00%)	Adverse Events	11
Fatigue0/6 (0.00%)	Adverse Events	12
Death NOS1/6 (16.67%)	Adverse Events	13
death	OAE:0000632	0-5
Infection with grade 3 or 4 neutrophils0/6 (0.00%)	Adverse Events	14
Adverse Events 2:	Adverse Events	15
Total: 6/6 (100.00%)	Adverse Events	16
Anemia0/6 (0.00%)	Adverse Events	17
Constipation0/6 (0.00%)	Adverse Events	18
Mucositis2/6 (33.33%)	Adverse Events	19
Vomiting1/6 (16.67%)	Adverse Events	20
Dehydration1/6 (16.67%)	Adverse Events	21
Abdominal pain0/6 (0.00%)	Adverse Events	22
Small intestinal obstruction0/6 (0.00%)	Adverse Events	23
Nausea0/6 (0.00%)	Adverse Events	24
Ascites0/6 (0.00%)	Adverse Events	25
Diarrhea0/6 (0.00%)	Adverse Events	26
Fatigue0/6 (0.00%)	Adverse Events	27
Death NOS0/6 (0.00%)	Adverse Events	28
death	OAE:0000632	0-5
Infection with grade 3 or 4 neutrophils1/6 (16.67%)	Adverse Events	29
